Aclasta is a medicine used for the treatment and prevention of osteoporosis of various aetiologies, including treatment for women suffering from osteoporosis during menopause. It is also recommended for the treatment of deforming osteitis (Paget's disease), male osteoporosis, reducing the number of fractures (hips, spine, others), and strengthening the bone skeleton. This product can be used as a treatment for the above due to its ability to increase bone tissue density.
An important component of Aclasta is Zoledronic Acid, which has the ability of inhibiting bone resorption. It also has a selective effect due to it’s similarity in composition with mineralized bone tissue. The duration of action occurs as a result of an increased bond between Zoledronic acid and bone minerals, and the active center of its main molecular target - the enzyme farnesyl pyrophosphate.
When patients with osteoporosis are treated with Aclasta there is a noticeable drop in the bones’ metabolism levels. For women undergoing this treatment menopause is restored within a 12-week period.